Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.64 |
| ▸ | CDK2 | P24941 | 4/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.64 |
| ▸ | CDK4 | P11802 | 7/20 | 0.58 |
| ▸ | CCND1 | P24385 | 7/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.58 |
| ▸ | CDK9 | P50750 | 5/20 | 0.58 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.58 |
| ▸ | CDK11A | Q9UQ88 | 5/20 | 0.58 |
| ▸ | LTK | P29376 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.54 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340809 | 0.99 | CCNA2 (0.63) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL4337539 | 0.94 | CCNA2 (0.61) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL4336260 | 0.92 | CDK4 (0.56) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL4333266 | 0.92 | CCNA2 (0.58) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL4345089 | 0.91 | CDK4 (0.55) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL4337579 | 0.90 | CCNA2 (0.60) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL14508264 | 0.90 | CDK4 (0.59) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL4333446 | 0.90 | CCNA2 (0.59) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL13785100 | 0.90 | CDK4 (0.61) | CCNA2CDK2CDK5CDK5R1CDK4 | |
| SCHEMBL4337513 | 0.89 | CCNA2 (0.60) | CCNA2CDK2CDK5CDK5R1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740576-B1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | claimed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | claimed |
| EP-1740576-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. Hoffman-la Roche AG (CH) | 2007-01-10 | — | — | EP | claimed |
| WO-2005103034-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. HOFFMAN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | claimed |
| US-20050239843-A1 | Diaminothiazoles | DING QINGJIE | 2005-10-27 | — | — | US | claimed |
| EP-1740576-B1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1740576-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. Hoffman-la Roche AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103034-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. HOFFMAN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239843-A1 | Diaminothiazoles | DING QINGJIE | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239843-A1 | Diaminothiazoles | CDK4, CDK2, CDK1 | CCNA2 30/4885CDK2 2/4885CDK5 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.